
PASSAGE BIO (PASG) Stock Forecast & Price Target
PASSAGE BIO (PASG) Analyst Ratings
Bulls say
Passage Bio is currently focused on the development and advancement of cutting-edge, one-time gene therapies for neurodegenerative diseases and has a strong pipeline, including the promising PBFT02 asset. While the company faces some regulatory hurdles, it has a strong cash position and has adjusted its penetration assumptions and launch timelines in a conservative manner, resulting in a new price target of $23.
Bears say
Passage Bio is facing regulatory uncertainties with their PBFT02 gene therapy for FTD-GRN and potential setbacks in clinical trial design. Their current cash balance of $46.3M may provide a runway into 1Q27, but the lack of flexibility from the FDA and potential reduction in OpEx could create challenges for the company. While there is potential for positive biomarker data and regulatory feedback in the coming quarters, the negative outlook and high-risk nature of the biotech industry may not make this stock an attractive investment opportunity.
This aggregate rating is based on analysts' research of PASSAGE BIO and is not a guaranteed prediction by Public.com or investment advice.
PASSAGE BIO (PASG) Analyst Forecast & Price Prediction
Start investing in PASSAGE BIO (PASG)
Order type
Buy in
Order amount
Est. shares
0 shares